# US 2017/0285031 A1 · Microplate and In Vitro Diagnostic Kit for HPV 16/E7 Oncoprotein Detection and Preparation Method Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285031 A1
- Document ID: US20170285031A1
- Status: Published application
- Kind: A1
- Application number: 15/497,228
- Filed: 2017-04-26
- Published: 2017-10-05
- Earliest claimed: 2016-02-26
- Inventors: Jinchao MIAO
- Web page: https://patentgrep.com/patent/US20170285031A1

## CPC

- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 33/57575: {involving oncogenic proteins}
- G01N 2333/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a microplate, an in vitro diagnostic kit for HPV type 16 E7 oncoprotein detection and a preparation method thereof The in vitro diagnostic kit is comprised of a microplate pre-coated with an HPV type 16 E7 antibody and an HRP-labeled HPV type 16 E7 antibody with concentration of 0.05-0.4 μg/ml, wherein the amount of the antibody in each microwell of the microplate is 0.05-0.5 μg. The in vitro diagnostic kit is used for directly detecting the expression of high-risk HPV-associated oncoprotein and the expression level, and thus has a clear judgment on the infection degree of high-risk HPV, and facilitates subsequent treatment.

## Claims

### Claim 1

A microplate for an HPV type 16 E7 oncoprotein detection, wherein the microplate is pre-coated with an HPV type 16 E7 antibody.

### Claim 2 (depends on 1)

The microplate according to claim 1, wherein an amount of the HPV type 16 E7 antibody in each microwell of the microplate is 0.05-0.5 μg.

### Claim 3 (depends on 1)

A method for preparing the microplate according to claim 1, comprising:
taking an HPV type 16 E7 antibody, adding a coating buffer to microwells at an amount of 100 μl/microwell and standing at 4° C. overnight (16-18 h);
washing the microwells with a washing solution five times at an amount of 300 μl/microwell;
adding a blocking solution to the microwells at an amount of 300 μl/microwell, and standing at 37° C. for 1-2h for blocking;
suction-drying in a drying room (18-26° C.) and sealing in vacuum (2-8° C.) to obtain a microplate coated with the HPV type 16 E7 antibody, and drying and storing,
wherein the coating buffer is prepared by adding 0.5-5 mg of HPV type 16 E7 antibody to 1000 ml of buffer, and the buffer is comprised of 1.59 g/L of Na2CO3 and 2.93 g/L of NaHCO3; the washing solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 0.5 ml/L of Tween-20, and 0.3 ml/L of Proclin 300; the blocking solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 10 g/L of BAS, 25 g/L of sucrose and 0.3 ml/L of Proclin 300.

### Claim 4 (depends on 2)

A method for preparing the microplate according to claim 2, comprising:
taking an HPV type 16 E7 antibody, adding a coating buffer to microwells at an amount of 100 μl/microwell and standing at 4° C. overnight (16-18 h);
washing the microwells with a washing solution five times at an amount of 300 μl/microwell;
adding a blocking solution to the microwells at an amount of 300 μl/microwell, and standing at 37° C. for 1-2 h for blocking;
suction-drying in a drying room (18-26° C.) and sealing in vacuum (2-8° C.) to obtain a microplate coated with the HPV type 16 E7 antibody, and drying and storing,
wherein the coating buffer is prepared by adding 0.5-5 mg of HPV type 16 E7 antibody to 1000 ml of buffer, and the buffer is comprised of 1.59 g/L of Na2CO3 and 2.93 g/L of NaHCO3; the washing solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 0.5 ml/L of Tween-20, and 0.3 ml/L of Proclin 300; the blocking solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 10 g/L of BAS, 25 g/L of sucrose and 0.3 ml/L of Proclin 300.

### Claim 5

An in vitro diagnostic kit for an HPV type 16 E7 oncoprotein detection, comprising:
a microplate pre-coated with an HPV type 16 E7 antibody, wherein an amount of the HPV type 16 E7 antibody in each microwell of the microplate is 0.05-0.5 μg; and
an HRP-labeled HPV type 16 E7 antibody with a concentration of 0.05-0.4 μg/ml.

### Claim 6 (depends on 5)

The in vitro diagnostic kit according to claim 5, further comprising a human cervical exfoliated cell lysis buffer.

### Claim 7 (depends on 6)

The in vitro diagnostic kit according to claim 6, wherein the human cervical exfoliated lysis buffer is comprised of 0.05%-l% of surfactant, 10 mM-1 M of buffer and 1 mM-10 mM of protease inhibitor.

### Claim 8 (depends on 7)

The in vitro diagnostic kit according to claim 7, wherein the surfactant is one or more of Tween 20, Triton-100 or sodium dodecylsulfonate, the buffer is phosphate-buffered saline, Tris-HCl or a carbonate solution, and the protease inhibitor is one or more of cystatin, PMSF or Antipain.

### Claim 9 (depends on 5)

The in vitro diagnostic kit according to claim 5, wherein a method for preparing the microplate pre-coated with the HPV type 16 E7 antibody is comprised of following steps:
taking the HPV type 16 E7 antibody, adding a coating buffer to the microwells at an amount of 100 μl/microwell and standing at 4° C. overnight (16-18 h);
washing the microwells with a washing solution five times at an amount of 300 μl/microwell;
adding a blocking solution to the microwells at an amount of 300 μl/microwell, and standing at 37° C. for 1-2 h for blocking;
suction-drying in a drying room (18-26° C.) and sealing in vacuum (2-8° C.) to obtain a microplate coated with the HPV type 16 E7 antibody, and drying and storing,
wherein the coating buffer is prepared by adding 0.5-5 mg of HPV type 16 E7 antibody to 1000 ml of buffer, and the buffer is comprised of 1.59 g/L of Na2CO3 and 2.93 g/L of NaHCO3; the washing solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 0.5 ml/L of Tween-20, and 0.3 ml/L of Proclin 300; the blocking solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 10 g/L of BAS, 25 g/L of sucrose and 0.3 ml/L of Proclin 300.

### Claim 10 (depends on 6)

The in vitro diagnostic kit according to claim 6, wherein a method for preparing the microplate pre-coated with the HPV type 16 E7 antibody is comprised of following steps:
taking the HPV type 16 E7 antibody, adding a coating buffer to the microwells at an amount of 100 μl/microwell and standing at 4° C. overnight (16-18 h);
washing the microwells with a washing solution five times at an amount of 300 μl/microwell;
adding a blocking solution to the microwells at an amount of 300 μl/microwell, and standing at 37° C. for 1-2 h for blocking;
suction-drying in a drying room (18-26° C.) and sealing in vacuum (2-8° C.) to obtain a microplate coated with the HPV type 16 E7 antibody, and drying and storing,
wherein the coating buffer is prepared by adding 0.5-5 mg of HPV type 16 E7 antibody to 1000 ml of buffer, and the buffer is comprised of 1.59 g/L of Na2CO3 and 2.93 g/L of NaHCO3; the washing solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 0.5 ml/L of Tween-20, and 0.3 ml/L of Proclin 300; the blocking solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 10 g/L of BAS, 25 g/L of sucrose and 0.3 ml/L of Proclin 300.

### Claim 11 (depends on 7)

The in vitro diagnostic kit according to claim 7, wherein a method for preparing the microplate pre-coated with the HPV type 16 E7 antibody is comprised of following steps:
taking the HPV type 16 E7 antibody, adding a coating buffer to the microwells at an amount of 100 μl/microwell and standing at 4° C. overnight (16-18 h);
washing the microwells with a washing solution five times at an amount of 300 μl/microwell;
adding a blocking solution to the microwells at an amount of 300 μl/microwell, and standing at 37° C. for 1-2 h for blocking;
suction-drying in a drying room (18-26° C.) and sealing in vacuum (2-8° C.) to obtain a microplate coated with the HPV type 16 E7 antibody, and drying and storing,
wherein the coating buffer is prepared by adding 0.5-5 mg of HPV type 16 E7 antibody to 1000 ml of buffer, and the buffer is comprised of 1.59 g/L of Na2CO3 and 2.93 g/L of NaHCO3; the washing solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 0.5 ml/L of Tween-20, and 0.3 ml/L of Proclin 300; the blocking solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 10 g/L of BAS, 25 g/L of sucrose and 0.3 ml/L of Proclin 300.

### Claim 12 (depends on 8)

The in vitro diagnostic kit according to claim 8, wherein a method for preparing the microplate pre-coated with the HPV type 16 E7 antibody is comprised of following steps:
taking the HPV type 16 E7 antibody, adding a coating buffer to the microwells at an amount of 100 μl/microwell and standing at 4° C. overnight (16-18 h);
washing the microwells with a washing solution five times at an amount of 300 μl/microwell;
adding a blocking solution to the microwells at an amount of 300 μl/microwell, and standing at 37° C. for 1-2 h for blocking;
suction-drying in a drying room (18-26° C.) and sealing in vacuum (2-8° C.) to obtain a microplate coated with the HPV type 16 E7 antibody, and drying and storing,
wherein the coating buffer is prepared by adding 0.5-5 mg of HPV type 16 E7 antibody to 1000 ml of buffer, and the buffer is comprised of 1.59 g/L of Na2CO3 and 2.93 g/L of NaHCO3; the washing solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 0.5 ml/L of Tween-20, and 0.3 ml/L of Proclin 300; the blocking solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 10 g/L of BAS, 25 g/L of sucrose and 0.3 ml/L of Proclin 300.

### Claim 13

A preparation method of an in vitro diagnostic kit for an HPV type 16 E7 oncoprotein detection, comprising:
1) preparing a microplate pre-coated with an HPV type 16 E7 antibody which comprises
taking the HPV type 16 E7 antibody, adding a coating buffer to microwells at an amount of 100 μl/microwell and standing at 4° C. overnight (16-18 h);
washing the microwells with a washing solution five times at an amount of 300 μl/microwell;
adding a blocking solution to the microwells at an amount of 300 μl/microwell, and standing at 37° C. for 1-2 h for blocking;
suction-drying in a drying room (18-26° C.) and sealing in vacuum (2-8° C.) to obtain a microplate coated with the HPV type 16 E7 antibody, and drying and storing,
wherein the coating buffer is prepared by adding 0.5-5 mg of HPV type 16 E7 antibody to 1000 ml of buffer, and the buffer is comprised of 1.59 g/L of Na2CO3 and 2.93 g/L of NaHCO3; the washing solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 0.5 ml/L of Tween-20, and 0.3 ml/L of Proclin 300; the blocking solution is comprised of 1.44 g/L of Na2HPO4, 0.24 g/L of KH2PO4, 8 g/L of NaCl, 0.2 g/L of KCl, 10 g/L of BAS, 25 g/L of sucrose and 0.3 ml/L of Proclin 300;
2) preparing calibrators and quality control samples which comprises
preparing HPV type 16 E7 oncoprotein detection calibrators 0, 1, 2, 3, 4 and 5: taking lyophilized powder as the calibrators, and respectively adding 1 ml ddH2O for dissolving, wherein linear concentrations of calibrator solutions are 0, 10, 20, 40, 80, and 160 ng/ml, respectively;
preparing HPV type 16 E7 oncoprotein detection quality control samples 1 and 2: taking lyophilized powder as the quality control samples, and respectively adding 1 ml ddH2O for dissolving, wherein concentrations are 10 and 80 ng/ml, respectively;
3) preparing an HRP-labeled HPV type 16 E7 antibody which comprises
labeling with a sodium periodate method, adding an HRP stabilizer, mixing thoroughly and storing at 2-8° C., wherein a concentration of the HRP-labeled HPV type 16 E7 antibody is 0.05-0.4 μg/ml;
4) preparing a human cervical exfoliated lysis buffer which comprises
preparing 0.05%-1% (vol/vol) of surfactant with 10 mM-1 M of buffer and adding a protease inhibitor with final concentration of 1 mM-10 mM before use,
wherein the surfactant is one or more of Tween 20, Triton-100 or sodium dodecylsulfonate; the buffer is phosphate-buffered saline, Tris-HCl or a carbonate solution, and the protease inhibitor is one or more of cystatin, PMSF or Antipain;
5) preparing a concentrated washing solution (20×) which comprises adding 28.8 g of Na2HPO4.12H2O, 4.8 g of KH2PO4, 160 g of NaCl, 4 g of KCl, 10 ml of Tween-20, and 6 ml of Proclin 300 to ddH2O, diluting to 1000 ml, mixing thoroughly and storing at room temperature; and
6) directly obtaining a substrate solution and a sealing film by purchasing.
